IGI Laboratories (IG) 7.79 $IG
Technical Roundup on Consumer Staples Equities -- Lorillard, Procter and Gamble, Colgate-Palmolive, Kimberly-Clark, and IGI Laboratories
PR Newswire - Thu Sep 11, 8:25AM CDT
On Wednesday, September 10, 2014, the NASDAQ Composite ended at 4,586.52, up 0.75%, the Dow Jones Industrial Average finished the day 0.32% higher at 17,068.71, and the S&P 500 closed at 1,995.69, up 0.36%. The gains were broad based with seven out of ten sectors finishing the session in positive. The S&P 500 Consumer Staples Sector Index ended the day at 465.25, up 0.43%, with the index advancing 0.51% in the previous three months. Investor-Edge has initiated coverage on the following equities: Lorillard Inc. (NYSE: LO), The Procter and Gamble Company (NYSE: PG), Colgate-Palmolive Company (NYSE: CL), Kimberly-Clark Corporation (NYSE: KMB), and IGI Laboratories Inc. (NYSE MKT: IG). Free research on these five companies can be accessed at:
Market Maker Surveillance Report. EPGL, EXEL, IG, T, INTC, GFI, Highest Net Sell Volume and Negative Price Friction For Tuesday, September 2nd 2014
M2 - Thu Sep 04, 9:47AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4916 companies with "abnormal" market making, 2511 companies with positive Friction Factors and 2570 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Tuesday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. EP GLOBAL COMMUNICATIONS INC (OTC:EPGL), Exelixis Inc (NASDAQ:EXEL), IGI Laboratories Inc (NYSE:IG), AT&T Inc (NYSE:T), INTEL CORPORATION (NASDAQ:INTC), Gold Fields Ltd (NYSE:GFI). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
IGI, Laboratories, Inc. (IG) in Focus: Stock Rises 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 8:32AM CDT
IGI, Laboratories, Inc. (IG) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
IGI, Laboratories (IG) Jumps: Stock Adds 6.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 7:51AM CDT
IGI, Laboratories, Inc. (IG) was a big mover last session, as its shares rose nearly 7% on the day.
IGI, Laboratories (IG) in Focus: Stock Rises 10.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 8:39AM CDT
IGI, Laboratories, Inc. (IG) was a big mover last session, as its shares rose nearly 11% on the day.
IGI Laboratories Announces Second Quarter 2014 Results
PR Newswire - Thu Jul 24, 3:02PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic drug development and manufacturing company, announced its financial results for the second quarter ended June 30, 2014.
IGI Laboratories, Inc. Announces Change To Its Board Of Directors
PR Newswire - Thu Jul 24, 3:02PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, today announced it has accepted Damian Finio's resignation from its Board of Directors. Mr. Finio has accepted a senior level finance position at a pharmaceutical company, and under the terms of his acceptance of his new position, Mr. Finio will be unable to continue in his role as Director for IGI Laboratories, Inc. The effective date of his resignation will be August 11, 2014. The Company has begun a search to replace Mr. Finio on its Board of Directors.
IGI Laboratories To Hold Conference Call For 2nd Quarter 2014 Results
PR Newswire - Fri Jul 18, 7:00AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, announced the Company will hold a conference call at 4:15 pm ET on Thursday, July 24, 2014 to discuss the 2nd quarter 2014 results.
IGI Laboratories concludes public offering at USD5.00 per share
M2 - Thu Jul 03, 5:52AM CDT
Topical drug company IGI Laboratories (NYSE MKT:IG) reported on Wednesday the sale of an aggregate of 5,347,500 common stock in the public offering at USD5.00 per share.
IGI Laboratories Announces Closing Of Underwritten Offering Including Over-Allotment Option
PR Newswire - Wed Jul 02, 3:05PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG; IGI or the Company), today announced the closing of its previously announced underwritten public offering of shares of its common stock, including all 697,500 shares subject to the underwriters' over-allotment option. After giving effect to the exercise of the over-allotment option, the Company sold an aggregate of 5,347,500 shares of common stock in the offering at a public offering price of $5.00 per share. The net proceeds of the offering are expected to be approximately $25.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.
IGI Laboratories (IG) Worth Watching: Stock Rises 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:25AM CDT
IGI Laboratories (IG) was a big mover last session, with shares rising over 6% on the day.
IGI Laboratories Added To The Russell 3000 Index
PR Newswire - Mon Jun 30, 1:08PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG; IGI or the Company), a specialty generic topical pharmaceutical company, has been added as a member of the broad-market Russell 3000® Index after the equity markets closed on June 27 as Russell Investments reconstituted its comprehensive family of global indexes.
IGI Laboratories Prices $23.3 Million Underwritten Offering
PR Newswire - Fri Jun 27, 7:04AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG; IGI or the Company), today announced the pricing of its previously announced underwritten public offering of 4,650,000 shares of its common stock at a price to the public of $5.00 per share. IGI has also granted the underwriters a 30-day option to purchase up to an aggregate of 697,500 additional shares of common stock at the public offering price to cover over-allotments, if any. The gross proceeds of the offering will be $23,250,000, assuming no exercise of the overallotment option. The offering is expected to close on July 2, 2014, subject to customary closing conditions.
GI Laboratories to launch diclofenac sodium topical solution 1.5% product on 28 March 2015 upon settlement with Mallickrodt
M2 - Fri Jun 27, 5:04AM CDT
Pharmaceutical company IGI Laboratories (NYSE MKT: IG) on Thursday reported an agreement to settle a declaratory judgment action concerning its filing of an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market a generic version of PENNSAID (diclofenac sodium topical solution) 1.5% w/w.
IGI Laboratories to launch public offering of common shares
M2 - Fri Jun 27, 4:59AM CDT
Pharmaceutical company IGI Laboratories (NYSE MKT:IG) said on Thursday that it intends to issue its common stock in an underwritten public offering.
IGI Laboratories Announces Public Offering Of Common Stock
PR Newswire - Thu Jun 26, 3:07PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG; IGI or the Company), today announced that it is offering shares of the Company's common stock in an underwritten public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
IGI Laboratories, Inc. Announces Joint Stipulation
PR Newswire - Thu Jun 26, 7:30AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced that it has entered into an agreement with Mallinckrodt LLC, Mallinckrodt Inc., and Nuvo Research, Inc. (TSX: NRI) (together Mallickrodt) to settle a declaratory judgment action brought by IGI, concerning IGI's filing of an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of PENNSAID (diclofenac sodium topical solution) 1.5% w/w. Under the terms of this agreement, Mallinckrodt granted IGI a non-exclusive license to launch its diclofenac sodium topical solution 1.5% product on March 28, 2015. IGI received tentative approval of its diclofenac sodium topical solution 1.5% from the FDA on May 7, 2014.
Weakness Seen in Alcobra (ADHD): Stock Falls 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 7:35AM CDT
Alcobra stock fell nearly 7% last trading session, reversing its recent uptrend
IGI Laboratories' 18th and 19th ANDA on file with US FDA
M2 - Mon Jun 23, 5:30AM CDT
Pharmaceutical company IGI Laboratories (NYSE MKT:IG) reported on Friday the submission of two additional abbreviated new drug application (ANDA), the 18th and 19th, to the US Food and Drug Administration (FDA).
IGI Laboratories, Inc. Announces 18th and 19th ANDA Submissions
PR Newswire - Fri Jun 20, 7:30AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted two additional abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA), which brings the Company's total number of ANDA submissions in 2014 to six, with seventeen submissions now pending at the FDA.
Technical Roundup on Consumer Staples Equities -- Lorillard, Procter and Gamble, Colgate-Palmolive, Kimberly-Clark, and IGI Laboratories
PR Newswire - Thu Sep 11, 8:25AM CDT
On Wednesday, September 10, 2014, the NASDAQ Composite ended at 4,586.52, up 0.75%, the Dow Jones Industrial Average finished the day 0.32% higher at 17,068.71, and the S&P 500 closed at 1,995.69, up 0.36%. The gains were broad based with seven out of ten sectors finishing the session in positive. The S&P 500 Consumer Staples Sector Index ended the day at 465.25, up 0.43%, with the index advancing 0.51% in the previous three months. Investor-Edge has initiated coverage on the following equities: Lorillard Inc. (NYSE: LO), The Procter and Gamble Company (NYSE: PG), Colgate-Palmolive Company (NYSE: CL), Kimberly-Clark Corporation (NYSE: KMB), and IGI Laboratories Inc. (NYSE MKT: IG). Free research on these five companies can be accessed at:
Market Maker Surveillance Report. EPGL, EXEL, IG, T, INTC, GFI, Highest Net Sell Volume and Negative Price Friction For Tuesday, September 2nd 2014
M2 - Thu Sep 04, 9:47AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4916 companies with "abnormal" market making, 2511 companies with positive Friction Factors and 2570 companies with negative Friction Factors. Here is a list of the top companies with the highest net sell volume on Tuesday and lowest negative price Friction (bearish). This means that there was more selling than buying in the stocks and their stock prices dropped faster with less Friction. EP GLOBAL COMMUNICATIONS INC (OTC:EPGL), Exelixis Inc (NASDAQ:EXEL), IGI Laboratories Inc (NYSE:IG), AT&T Inc (NYSE:T), INTEL CORPORATION (NASDAQ:INTC), Gold Fields Ltd (NYSE:GFI). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
IGI, Laboratories, Inc. (IG) in Focus: Stock Rises 5.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 8:32AM CDT
IGI, Laboratories, Inc. (IG) was a big mover last session, as the company saw its shares rise nearly 6% on the day.
IGI, Laboratories (IG) Jumps: Stock Adds 6.7% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 7:51AM CDT
IGI, Laboratories, Inc. (IG) was a big mover last session, as its shares rose nearly 7% on the day.
IGI, Laboratories (IG) in Focus: Stock Rises 10.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 8:39AM CDT
IGI, Laboratories, Inc. (IG) was a big mover last session, as its shares rose nearly 11% on the day.
IGI Laboratories Announces Second Quarter 2014 Results
PR Newswire - Thu Jul 24, 3:02PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic drug development and manufacturing company, announced its financial results for the second quarter ended June 30, 2014.
IGI Laboratories, Inc. Announces Change To Its Board Of Directors
PR Newswire - Thu Jul 24, 3:02PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, today announced it has accepted Damian Finio's resignation from its Board of Directors. Mr. Finio has accepted a senior level finance position at a pharmaceutical company, and under the terms of his acceptance of his new position, Mr. Finio will be unable to continue in his role as Director for IGI Laboratories, Inc. The effective date of his resignation will be August 11, 2014. The Company has begun a search to replace Mr. Finio on its Board of Directors.
IGI Laboratories To Hold Conference Call For 2nd Quarter 2014 Results
PR Newswire - Fri Jul 18, 7:00AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based topical generic drug development and manufacturing company, announced the Company will hold a conference call at 4:15 pm ET on Thursday, July 24, 2014 to discuss the 2nd quarter 2014 results.
IGI Laboratories concludes public offering at USD5.00 per share
M2 - Thu Jul 03, 5:52AM CDT
Topical drug company IGI Laboratories (NYSE MKT:IG) reported on Wednesday the sale of an aggregate of 5,347,500 common stock in the public offering at USD5.00 per share.
IGI Laboratories Announces Closing Of Underwritten Offering Including Over-Allotment Option
PR Newswire - Wed Jul 02, 3:05PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG; IGI or the Company), today announced the closing of its previously announced underwritten public offering of shares of its common stock, including all 697,500 shares subject to the underwriters' over-allotment option. After giving effect to the exercise of the over-allotment option, the Company sold an aggregate of 5,347,500 shares of common stock in the offering at a public offering price of $5.00 per share. The net proceeds of the offering are expected to be approximately $25.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.
IGI Laboratories (IG) Worth Watching: Stock Rises 6.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:25AM CDT
IGI Laboratories (IG) was a big mover last session, with shares rising over 6% on the day.
IGI Laboratories Added To The Russell 3000 Index
PR Newswire - Mon Jun 30, 1:08PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG; IGI or the Company), a specialty generic topical pharmaceutical company, has been added as a member of the broad-market Russell 3000® Index after the equity markets closed on June 27 as Russell Investments reconstituted its comprehensive family of global indexes.
IGI Laboratories Prices $23.3 Million Underwritten Offering
PR Newswire - Fri Jun 27, 7:04AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG; IGI or the Company), today announced the pricing of its previously announced underwritten public offering of 4,650,000 shares of its common stock at a price to the public of $5.00 per share. IGI has also granted the underwriters a 30-day option to purchase up to an aggregate of 697,500 additional shares of common stock at the public offering price to cover over-allotments, if any. The gross proceeds of the offering will be $23,250,000, assuming no exercise of the overallotment option. The offering is expected to close on July 2, 2014, subject to customary closing conditions.
GI Laboratories to launch diclofenac sodium topical solution 1.5% product on 28 March 2015 upon settlement with Mallickrodt
M2 - Fri Jun 27, 5:04AM CDT
Pharmaceutical company IGI Laboratories (NYSE MKT: IG) on Thursday reported an agreement to settle a declaratory judgment action concerning its filing of an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) seeking approval to market a generic version of PENNSAID (diclofenac sodium topical solution) 1.5% w/w.
IGI Laboratories to launch public offering of common shares
M2 - Fri Jun 27, 4:59AM CDT
Pharmaceutical company IGI Laboratories (NYSE MKT:IG) said on Thursday that it intends to issue its common stock in an underwritten public offering.
IGI Laboratories Announces Public Offering Of Common Stock
PR Newswire - Thu Jun 26, 3:07PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG; IGI or the Company), today announced that it is offering shares of the Company's common stock in an underwritten public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
IGI Laboratories, Inc. Announces Joint Stipulation
PR Newswire - Thu Jun 26, 7:30AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced that it has entered into an agreement with Mallinckrodt LLC, Mallinckrodt Inc., and Nuvo Research, Inc. (TSX: NRI) (together Mallickrodt) to settle a declaratory judgment action brought by IGI, concerning IGI's filing of an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of PENNSAID (diclofenac sodium topical solution) 1.5% w/w. Under the terms of this agreement, Mallinckrodt granted IGI a non-exclusive license to launch its diclofenac sodium topical solution 1.5% product on March 28, 2015. IGI received tentative approval of its diclofenac sodium topical solution 1.5% from the FDA on May 7, 2014.
Weakness Seen in Alcobra (ADHD): Stock Falls 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 7:35AM CDT
Alcobra stock fell nearly 7% last trading session, reversing its recent uptrend
IGI Laboratories' 18th and 19th ANDA on file with US FDA
M2 - Mon Jun 23, 5:30AM CDT
Pharmaceutical company IGI Laboratories (NYSE MKT:IG) reported on Friday the submission of two additional abbreviated new drug application (ANDA), the 18th and 19th, to the US Food and Drug Administration (FDA).
IGI Laboratories, Inc. Announces 18th and 19th ANDA Submissions
PR Newswire - Fri Jun 20, 7:30AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based generic topical pharmaceutical company, today announced it has submitted two additional abbreviated new drug application (ANDA) to the U.S. Food and Drug Administration (FDA), which brings the Company's total number of ANDA submissions in 2014 to six, with seventeen submissions now pending at the FDA.
